In a report released today, James Molloy from Alliance Global Partners initiated coverage with a Buy rating on CNS Pharmaceuticals (CNSP – ...

Alliance Global Partners initiated coverage of CNS Pharmaceuticals (CNSP) with a Buy rating and $4 price target CNS is a clinical-stage ...

CHARLOTTESVILLE, Va. and SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating cardiometabolic diseases driven ...

(Image Credits: Pixabay) Amid the growing burden of non-communicable diseases and ageing population, the pharmaceutical sector has thrived tremendously over the recent years. Industry leaders ...

“My Economy” tells the story of the new economic normal through the eyes of people trying to make it, because we know the only numbers that really matter are the ones in your economy.

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...

This scenario indicates that 2025 will be a promising year for the pharma sector. A report by Axis Securities last month outlined a positive outlook for the pharmaceutical sector over the next three ...

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is pleased to announce the opening of the first clinical site for its lead asset, HG-CT-1, targeting relapsed ...

STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)--$MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in ...